Background: The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed. Methods and results: In a retrospective meta-analysis from six centres, we observed six cases of acute myeloid leukaemia (AML) (incidence 0.41% for patients with mean follow up after end of treatment of 3.6 years, n = 1.156; incidence 0.25% for all patients, n = 2.261). Potential influencing factors such as myelotoxic or glucocorticosteroid pretreatment/ cotreatment were present in all but one case of TRAL. Between 1990 and 2010, 11 cases of TRAL were reported to the Drug Commission of the German Medical Association (estimated risk of 0.09-0.13%). Conclusions: Regional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.
Introduction and purpose
Mitoxantrone (MX) is approved for the treatment of aggressive multiple sclerosis (MS) with respect to its immunosuppressive effects, especially for secondary progressive MS where treatment alternatives are sparse. Owing to its risk profile, MX use is restricted. In particular, therapy-related acute leukaemia (TRAL) has recently been discussed: whereas initial meta-analyses indicated a low risk of MX-associated TRAL in MS (0.07%) [Ghalie et al. 2002] , reports of regional higher TRAL incidence have attracted considerable attention (as reviewed by Marriott et al. [2010] and Pascual et al. [2009] ). A recent metaanalysis stated a risk of 0.81% of MX-associated TRAL, however, with large variability between studies [Marriott et al. 2010 ]. More recently prospective data from a French population (n = 802) indicated a more favourable haematologic safety profile with a TRAL incidence of 0.25% [Le Page et al. 2011 ].
Here we set out to evaluate the incidence of MX-associated TRAL in a large MX-treated MS cohort in a country with high MX usage.
Patients and methods
In a retrospective meta-analysis, data from six German academic MS centres were analysed (Table 1A) . The observation period began between 1993 and 2005 and ended between 2007 and 2010 (median 12.0 years, 95% confidence interval [CI] 7.9-16.4). Continuous variables were expressed as means and dichotomous variables as absolute numbers and percentages. For each variable, the 95% CI was estimated. To summarize the individual results, a meta-analysis with a random effects model was computed. I 2 and the p-value from the Q statistic were computed as measures for heterogeneity. All statistical analyses were performed using SAS Version 9.2 and R Version 2.10.0 (Package meta). Moreover, officially reported TRAL cases in the registry of the Drug Commission of the German Medical Association (DCGMA) and data from the German MS registry [Flachenecker et al. 2008 ] (and P. Flachenecker, unpublished data) are described. 
Results
Six TRAL cases were observed in the six major academic MS centres (Table 1A and B) . When only patients are analysed who were followed up for an average of 3.6 years, an incidence of 0.41% is estimated (n = 1.156 [Flachenecker et al. 2008 ] (and P. Flachenecker, unpublished data), estimated frequency of TRAL ranges between 0.09% and 0.13%.
Discussion and conclusions
Using two different approaches, we observe a considerably lower MX-associated TRAL incidence in Germany than in recent reports from other regions (as reviewed by Marriott et al. [2010] and Pascual et al. [2009] ). These in majority retrospective reports with low patient numbers offered partially incomplete data, e.g. concerning dosage, potential risk factors and diagnosis of leukaemia. Importantly, treatment protocols differ concerning intervals, dosages and cotreatments and were mostly without titration according to leukocyte counts as performed in the pivotal phase III trial . In a prospective albeit small study (n = 230, TRAL incidence 2.82%), MX therapy in five of six TRAL cases was initially administered in monthly intervals (10 mg/m 2 BSA) independent from leukocyte nadirs, and two TRAL patients had received azathioprine before or after MX treatment [Pascual et al. 2009 ]. As two TRAL patients in our series had either received MX induction therapy or azathioprine treatment, higher dosage over shorter time and myelotoxic cotreatments may represent independent risk factors. Concomitant GC treatment may pose an additional confounder since four cases had received GC with each MX cycle and GC have been demonstrated to increase intracellular MX concentration in vitro [Cotte et al. 2009 ]. However, in a prospective French study [Le Page et al. 2011] where the majority of the patients were treated with a monthly combination of MX and GC for a mean cumulative mitoxantrone dose of 78 mg/m 2 BSA a comparable TRAL incidence (0.25%) was observed (mean follow-up duration: 6.7 years).
Data on AML subtypes, outcome and latency to TRAL onset in our cohort (Table 1B) is comparable with previous reports [Pascual et al. 2009; Ellis and Boggild, 2009] and compatible with haematological data on secondary leukaemia after topoisomerase-II-inhibitor treatment (latency 0.5-5 years). At TRAL onset, three of six patients exhibited a lower cumulative dosage than previously suggested as a risk factor (60 mg/m 2 BSA) [Ellis and Boggild, 2009] ; thus, a hypothetical threshold dosage still needs to be defined. In two cases, dose adjustment due to pronounced leukocyte nadirs did not prevent TRAL development. These aspects might point to individual predisposition and argue for rapid bone marrow biopsy in long-lasting cytopenia despite dose reduction. Currently, potential pharmacogenetic risk factors [Cotte et al. 2009 ] are being investigated in a prospective study.
Despite the large cohort observed, our data has to be interpreted with caution due to the retrospective approach with different observation periods. Still, more recently two prospective albeit smaller studies have demonstrated TRAL incidences similar to the range reported here [Le Page et al. 2011; Rivera et al. 2009 ].
In summary, large regional variability of TRAL incidence may point to other confounding factors such as administration protocols and cotreatments. This emphasizes the urgent need for uniform treatment algorithms in addition to thorough postmarketing surveillance [Marriott et al. 2010 ] including ongoing haematologic screening for at least 5 years after the end of MX treatment [Le Page et al. 2011 ].
